Shortcuts 2024 2022 2021 2020

2024

  • Article on Partner CellProthera
    Read More

  • TCT MD
    Small Study Hints at Potential for HF Bone Marrow Cell Therapy: CardiAMP-HF Read More

2022

  • Fierce Biotech
    BioCardia's off-the-shelf cell therapy for heart failure to enter first-in-human study Read More

2021

  • Empowered Patient Podcast
    Optimizing Autologous Cell Therapy to Treat Cardiovascular Disease with Dr. Peter Altman Read More

  • UW Health
    UW Health Treats First Patient in U.S. with Investigational Cell Therapy for Heart Disease Read More

  • Greenbay CBS
    Neenah musician, educator pursues dream after being first in the world to undergo ‘Investigational Cell Therapy’ Read More

  • WBay.com
    Neenah man gets new lease on life after trial heart procedure Read More

  • Henry Ford Health System
    Henry Ford Health System Studies Novel Cell Therapy Aimed at Improving Heart Failure Symptoms Read More

  • Cell & Gene
    Inside BioCardia's CardiAMP Cell Therapy Read More

2020

  • BioTuesdays
    BioCardia developing autologous and allogenic cardiovascular cell therapies Read More

  • Pharmaceutical Technology
    BioCardia’s novel CardiAMP stem cell therapy closer to approval in heart failure Read More

press releases

18 Sep
2024 BioCardia Regains Full Compliance with Nasdaq Listing Requirements
09 Sep
2024 BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
30 Aug
2024 BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
29 Aug
2024 BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
21 Aug
2024 FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
13 Aug
2024 BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS